Alexander Röth

10.9k total citations · 4 hit papers
153 papers, 5.6k citations indexed

About

Alexander Röth is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Alexander Röth has authored 153 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Immunology, 79 papers in Hematology and 64 papers in Genetics. Recurrent topics in Alexander Röth's work include Complement system in diseases (74 papers), Blood groups and transfusion (56 papers) and Renal Diseases and Glomerulopathies (35 papers). Alexander Röth is often cited by papers focused on Complement system in diseases (74 papers), Blood groups and transfusion (56 papers) and Renal Diseases and Glomerulopathies (35 papers). Alexander Röth collaborates with scholars based in Germany, United States and United Kingdom. Alexander Röth's co-authors include Jeff Szer, Hubert Schrezenmeier, Antonio M. Risitano, S. G. O. Johansson, N‐I Max Kjellman, Peter Hillmen, Anita Hill, Jaroslaw P. Maciejewski, Petra Muus and Ulrich Dührsen and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Alexander Röth

140 papers receiving 5.4k citations

Hit Papers

The Complement Inhibitor Eculizumab in Paroxysmal Nocturn... 2006 2026 2012 2019 2006 2007 2019 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
    2006 878 citations Peter Hillmen, Jörg Schubert et al. profile →
  2. Immune Activation in Patients With Irritable Bowel Syndrome
    2007 523 citations Alexander Röth et al. profile →
  3. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
    2019 286 citations Wilma Barcellini, Catherine M. Broome et al. profile →
  4. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
    2021 249 citations Peter Hillmen, Jeff Szer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alexander Röth Germany 35 2.9k 1.9k 1.5k 1.4k 1.1k 153 5.6k
Élie Haddad Canada 46 3.2k 1.1× 1.9k 1.0× 615 0.4× 555 0.4× 363 0.3× 179 6.9k
Thierry Martin France 33 2.2k 0.8× 527 0.3× 462 0.3× 172 0.1× 436 0.4× 152 5.2k
K Whaley United Kingdom 34 2.2k 0.8× 905 0.5× 740 0.5× 259 0.2× 868 0.8× 198 4.7k
Raphaela Goldbach‐Mansky United States 49 4.4k 1.5× 1.6k 0.8× 255 0.2× 650 0.5× 482 0.4× 148 9.2k
Elias Toubi Israel 47 2.3k 0.8× 473 0.2× 893 0.6× 161 0.1× 340 0.3× 167 5.8k
Ivona Aksentijevich United States 44 4.3k 1.5× 1.4k 0.7× 230 0.2× 859 0.6× 346 0.3× 144 8.4k
Jordi Antón Spain 35 1.6k 0.5× 1.1k 0.6× 145 0.1× 241 0.2× 250 0.2× 172 4.5k
Michèlle Rosenzwajg France 39 3.2k 1.1× 384 0.2× 528 0.4× 239 0.2× 201 0.2× 103 6.0k
Edimara S. Reis United States 32 2.9k 1.0× 740 0.4× 370 0.2× 667 0.5× 364 0.3× 61 4.5k
Wilma Β. Bias United States 47 2.7k 0.9× 1.1k 0.6× 326 0.2× 153 0.1× 1.3k 1.2× 160 7.3k

Countries citing papers authored by Alexander Röth

Since Specialization
Citations

This map shows the geographic impact of Alexander Röth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Röth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Röth more than expected).

Fields of papers citing papers by Alexander Röth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Röth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Röth. The network helps show where Alexander Röth may publish in the future.

Co-authorship network of co-authors of Alexander Röth

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Röth. A scholar is included among the top collaborators of Alexander Röth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Röth. Alexander Röth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cosson, Valérie, Rong Fu, Austin Kulasekararaj, et al.. (2025). Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria. British Journal of Clinical Pharmacology. 91(5). 1479–1490.
2.
Kulasekararaj, Austin, Robert A. Brodsky, Hubert Schrezenmeier, et al.. (2025). Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria. Annals of Hematology. 104(1). 81–94. 2 indexed citations
3.
Röth, Alexander, Wilma Barcellini, Shripad Chitnis, et al.. (2024). Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results. Blood. 144(Supplement 1). 2457–2457. 1 indexed citations
4.
Kulasekararaj, Austin, Jarosław Czyż, Catherine Flynn, et al.. (2024). Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab or Eculizumab. Blood. 144(Supplement 1). 1323–1323. 1 indexed citations
5.
Röth, Alexander, et al.. (2024). Crizanlizumab in adult patients with sickle cell disease: a retrospective German analysis. SHILAP Revista de lepidopterología. 3. 2 indexed citations
6.
Dingli, David, Carlos de Castro, Austin Kulasekararaj, et al.. (2024). Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria. Hematology. 29(1). 2329030–2329030. 7 indexed citations
7.
Röth, Alexander, Austin Kulasekararaj, Phillip Scheinberg, & Jun‐ichi Nishimura. (2024). Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape. Immunotherapy. 16(20-22). 1185–1196. 1 indexed citations
8.
Röth, Alexander, et al.. (2024). Flexible Piezoelectric Nanocolumnar Composite Films as Flat-Panel Loudspeakers: Application and Modeling. ACS Applied Materials & Interfaces. 16(44). 60749–60761. 1 indexed citations
9.
10.
Röth, Alexander, Catherine M. Broome, Wilma Barcellini, et al.. (2023). Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Advances. 7(19). 5890–5897. 8 indexed citations
11.
Höchsmann, Britta, Régis Peffault de Latour, A. Bradford Hill, et al.. (2023). Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry. Annals of Hematology. 102(11). 2979–2988. 9 indexed citations
12.
Latour, Régis Peffault de, Jeff Szer, Ilene C. Weitz, et al.. (2022). Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. The Lancet Haematology. 9(9). e648–e659. 43 indexed citations
13.
Röth, Alexander, Wilma Barcellini, Tor Henrik Anderson Tvedt, et al.. (2022). Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study. Annals of Hematology. 101(10). 2169–2177. 13 indexed citations
14.
Karow, Axel, Monika Haubitz, Elisabeth Oppliger Leibundgut, et al.. (2021). Targeting Telomere Biology in Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. 22(13). 6653–6653. 10 indexed citations
15.
Broome, Catherine M., Alexander Röth, David J. Kuter, et al.. (2020). Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia. Blood. 136(Supplement 1). 14–15. 12 indexed citations
16.
Berentsen, Sigbjørn, et al.. (2019). Cold agglutinin disease: current challenges and future prospects. SHILAP Revista de lepidopterología. 1 indexed citations
17.
Sostelly, Alexandre, Antoine Soubret, Christoph Bucher, et al.. (2019). Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes. Blood. 134(Supplement_1). 1227–1227. 2 indexed citations
18.
Schrezenmeier, Hubert, Peter Bettelheim, Jens Panse, et al.. (2012). Recommendations for the diagnosis of paroxysmal nocturnal hemoglobinuria: a German-Austrian Consensus1). LaboratoriumsMedizin. 35(6). 2 indexed citations
19.
Fischer, L., Peter Martus, Michael Weller, et al.. (2008). Meningeal dissemination in primary CNS lymphoma. Neurology. 71(14). 1102–1108. 67 indexed citations
20.
Röth, Alexander, et al.. (2007). KoaLA - Integrierte Lern- und Arbeitswelten für die Universitäten 2.0.. DeLFI. 71(6). 221–232.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Élie Haddad Breakdown of academic impact, for papers by Thierry Martin Breakdown of academic impact, for papers by K Whaley Breakdown of academic impact, for papers by Raphaela Goldbach‐Mansky Breakdown of academic impact, for papers by Elias Toubi Breakdown of academic impact, for papers by Ivona Aksentijevich Breakdown of academic impact, for papers by Jordi Antón Breakdown of academic impact, for papers by Michèlle Rosenzwajg Breakdown of academic impact, for papers by Edimara S. Reis Breakdown of academic impact, for papers by Wilma Β. Bias
Rankless by CCL
2026